

Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i33.11840 World J Gastroenterol 2014 September 7; 20(33): 11840-11849 ISSN 1007-9327 (print) ISSN 2219-2840 (online) © 2014 Baishideng Publishing Group Inc. All rights reserved.

RETROSPECTIVE STUDY

Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester

Yu-Jun He, Wan-Ling Li, Bao-Hua Liu, Hui Dong, Zhi-Rong Mou, Yu-Zhang Wu

Yu-Jun He, Wan-Ling Li, Hui Dong, Zhi-Rong Mou, Yu-Zhang Wu, Institute of Immunology of PLA, the Third Military Medical University, Chongqing 400038, China

Yu-Jun He, Bao-Hua Liu, Department of General Surgery, Daping Hospital and Research Institute of Surgery, the Third Military Medical University, Chongqing 400042, China

Author contributions: He YJ and Mou ZR designed the research; He YJ, Li WL and Dong H performed the research; He YJ, Liu BH and Mou ZR analyzed the data; He YJ, Liu BH, Mou ZR and Wu YZ wrote the paper; Mou ZR and Wu YZ contributed equally to this work.

Supported by National Natural Science Foundation of China No. 30872466 and No. 30801096, the Natural Science Foundation of Chongqing No. 2011BB5032, and PLA Logistics Science Research during the 12th Five-Year Plan Period No. BWS11J041 Correspondence to: Zhi-Rong Mou, PhD, Institute of Immunology of PLA, the Third Military Medical University, Chongqing 400038, China. mouzr@yahoo.com

 Telephone: +86-23-68752680
 Fax: +86-23-68752789

 Received: January 2, 2014
 Revised: March 18, 2014

 Accepted: April 28, 2014
 Published online: September 7, 2014

Abstract

AIM: To investigate the molecular mechanisms of the anti-cancer activity of caffeic acid phenethyl ester (CAPE).

METHODS: Protein profiles of human colorectal cancer SW480 cells treated with or without CAPE were analysed using a two-dimensional (2D) electrophoresis gelbased proteomics approach. After electrophoresis, the gels were stained with Coomassie brilliant blue R-250. Digital images were taken with a GS-800 Calibrated Densitometer, and image analysis was performed using PDQuest 2-D Analysis software. The altered proteins following CAPE treatment were further identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry following a database search. The identified proteins were validated by Western blot and immunofluorescence assay.

RESULTS: CAPE induced human colorectal cancer cell apoptosis. Four up-regulated proteins and seven down-regulated proteins in colorectal cancer cells treated with CAPE were found. The identified downregulated proteins in CAPE-treated colorectal cancer cells were Triosephosphate Isomerase (Tim), Proteasome subunit alpha 4 (PSMA4) protein, Guanine nucleotide binding protein beta, Phosphoserine aminotransferase 1 (PSAT1), PSMA1, Myosin XVIIIB and Tryptophanyl-tRNA synthetase. Notably, CAPE treatment led to the down-regulation of PSAT1 and PSMA1, two proteins that have been implicated in tumorigenesis. The identified up-regulated proteins were Annexin A4, glyceraldehyde-3-phosphate dehydrogenase, Glucosamine-6-phosphate deaminase 1 (GNPDA1), and Glutathione peroxidase (GPX-1). Based on high match scores and potential role in cell growth control, PSMA1, PSAT1, GNPDA1 and GPX-1 were further validated by Western blotting and immunofluorescence assay. PSMA1 and PSAT1 were down-regulated, while GNPDA1 and GPX-1 were up-regulated in CAPE-treated colorectal cancer cells.

CONCLUSION: These differentiated proteins in colorectal cancer cells following CAPE treatment, may be potential molecular targets of CAPE and involved in the anti-cancer effect of CAPE.

 $\ensuremath{\textcircled{C}}$ 2014 Baishideng Publishing Group Inc. All rights reserved.

Key words: Caffeic acid phenethyl ester; Colorectal cancer; Proteomics; Two-dimensional electrophoresis; Mass spectrometry

Core tip: To investigate the molecular mechanisms of the anti-cancer activity of caffeic acid phenethyl ester (CAPE), CAPE-treated colorectal cancer SW480 cells were analysed by a 2D-gel based proteomics approach. Four up-regulated proteins and seven down-regulated proteins in CAPE-treated SW480 cells were found and further identified by matrix-assisted laser desorption/



ionization time-of-flight mass spectrometry following a database search. The down-regulated proteins, PSMA1 and PSAT1 and up-regulated proteins GNPDA1 and GPX-1 were validated by Western blotting. The two tumorigenesis associated proteins, PSMA1 and PSAT1, were further confirmed by immunofluorescence assay. These differentiated proteins in colorectal cancer cells following CAPE treatment, may be potential molecular targets of CAPE and involved in the anti-cancer effect of CAPE.

He YJ, Li WL, Liu BH, Dong H, Mou ZR, Wu YZ. Identification of differential proteins in colorectal cancer cells treated with caffeic acid phenethyl ester. *World J Gastroenterol* 2014; 20(33): 11840-11849 Available from: URL: http://www.wjgnet. com/1007-9327/full/v20/i33/11840.htm DOI: http://dx.doi. org/10.3748/wjg.v20.i33.11840

INTRODUCTION

Colorectal cancer (CRC) is one of the most commonly diagnosed malignancies and the third deadliest cancer in humans. In 2012, it was estimated that 143460 people in the United States had been diagnosed with colorectal cancer and that 51690 will die from this disease^[1,2]. In the last few decades, enormous advances in the diagnosis and treatment of CRC have been made, and molecular biology has clarified some of the mechanisms involved in the carcinogenic process. However, patient prognosis is still poor; after curative resections, approximately 50% of patients succumb to recurrent and metastatic disease during the first 2 years of follow-up. For this reason, novel anticancer drugs for CRC are urgently needed.

Caffeic acid phenethyl ester (CAPE), a component of propolis is a phenolic antioxidant. CAPE has been shown to help in host defence through its anti-viral and anti-bacterial activity. In addition, the immunoregulatory properties, anti-inflammatory activity and anti-cancer activity of CAPE have been reported. Several studies have demonstrated that CAPE has anti-proliferative effects by inducing apoptosis in various tumour cells *in vitro*^[3-7] and *in vivo*^[8,9]. CAPE also inhibits the development of azoxymethane-induced aberrant crypts in the colon of rats^[10].

Multiple molecular mechanisms seem to be involved in the anti-cancer effects of CAPE. We have previously shown that decreased β -catenin and associated signalling pathways may mediate the anti-cancer effects of CAPE^[2]. It has been reported that CAPE inhibits tumor necrosis factor alpha-dependent nuclear factor kappa beta (NF κ B) activation *via* direct inhibitory protein kappaB kinase inhibition and Nuclear factor-erythroid 2 p45 (NF-E2)-related factor 2 pathway activation^[11]. Previous studies have also shown that Mcl-1 down-regulation, Bcl-2 expression, and Bax up-regulation, as well as activation of caspase-8, caspase-3, and PARP, are associated with CAPE-dependent cellular apoptosis^[12,13]. However, the exact anti-tumour mechanism of CAPE is not fully understood. To understand the mechanism of the anti-cancer activity of CAPE, CAPE-treated colorectal cancer SW480 cells were analysed by a 2D-gel based proteomics approach. Differentially expressed proteins were identified by mass spectrometry and then validated by Western blotting and confocal microscopy.

MATERIALS AND METHODS

Cell culture

The human CRC cell line SW480 was purchased from the American Type Culture Collection. The cells were cultured in RPMI-1640 medium supplemented with penicillin G (100 U/mL), streptomycin (100 μ g/mL), and 10% foetal calf serum. The cells were grown at 37 °C in a humidified atmosphere of 5% CO₂ and were routinely sub-cultured using 0.25% (w/v) trypsin-EDTA solution. All cell culture reagents were purchased from GIBCO (Carlsbad, United States). For CAPE treatment, CAPE was dissolved in DMSO and adjusted to a working concentration with culture medium before use (DMSO concentration was 0.1%). CAPE was added to the culture medium on the second day at a working concentration of 10 μ g/mL.

TUNEL staining

SW480 cells were grown on poly-L-lysine coated slides in a six-well plate. After treatment with or without CAPE for 48 h, the slides were gently washed three times in 0.1 mol/L PBS (pH = 7.4) and fixed with 4% paraformaldehyde. To determine cellular apoptosis, terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assays were performed using the TUNEL Detection kit (Boehringer Mannheim, Mannheim, Germany) according to the manufacturer's instructions. All samples were observed under a microscope. Cell apoptosis was determined by counting TUNEL positive cells under a light microscope at \times 40 objective.

Protein separation by 2-D electrophoresis

SW480 cells were cultured in RPMI 1640 medium with or without CAPE (10 μ g/mL) for 48 h. The cells were carefully collected using a cell scraper. All reagents for 2D electrophoresis were obtained from Amersham Pharmacia Biotech (Uppsala, Sweden), except those otherwise indicated. To perform 2D electrophoresis, SW480 tumour cells were suspended in lysis buffer containing 40 mmol/ L Tris, 8 mol/L urea, 4% CHAPS, 60 mmol/L DTT, 0.8% IPG buffer (pH = 3-10), and protease inhibitor cocktail (Roche, Mannheim, Germany). Protein concentration was measured with the DC Protein Assay (BioRad, United States). Proteins (500 mg/gel) were loaded into IEF gels (pH = 3-10). The gels were immersed overnight in hydration buffer containing 8 M urea, 4% CHAPS, 60 mmol/L DTT, and 0.5% IPG buffer. After sample loading, IEF gels were run at 200 V for 1 h, 500 V for 1 h, 1000 V for 1 h and then were gradually increased to 8000 V for 5-6 h. Focusing was carried out at 35000 V h. After IEF, IPG strips were equilibrated twice in equilibration buffer (50 mmol/L Tris-HCl (pH = 8.8), 6 mol/L urea, 30% glycerol, 2% SDS). In the first equilibration, 100 mg of DTT was dissolved in 10 mL of equilibration buffer, and 400 mg of iodoacetamide was added in the second equilibration. The strips were then transferred onto vertical slab 12.5% SDS-PAGE gels and sealed with 0.5% low melting point agarose.

Image analysis

After electrophoresis, the gels were stained with Coomassie brilliant blue R-250. Digital images were taken with a GS-800 Calibrated Densitometer (BioRad, USA), and image analysis was performed with PDQuest 2-D Analysis software (BioRad, United States).

Protein in-gel enzyme digestion and identification

In-gel digestion was performed as described by Rosenfeld^[14]. Briefly, spots were excised from the stained gel, destained with 25 mmol/L ammonium bicarbonate/50% acetonitrile (ACN), and then dried with a SpeedVac plus SC1 10 (Savant Holbook, United States). The dried gels were rehydrated in trypsin solution (Promega, United States) at 37 °C overnight. After rehydration, peptides were first eluted with 5% trifluoroacetic acid (TFA) at 40 °C for 1 h, and then eluted with 2.5% TFA/50% ACN at 30 °C for 1 h. ACN was removed by centrifugation in a vacuum centrifuge. The peptides were concentrated using C18 pipette tips (Millipore, Bedford, MA, United States). Analysis was performed primarily using the matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass spectrometer (Bruker, Germany). Peptide mixtures were analysed using a saturated solution of α -cyano-4-hydroxycinnamic acid (Sigma, United States) in acetone containing 1% TFA. Peptides were selected in the mass range of 800-4000 Da. The peptide sequence was determined with MASCOT software. Sequence homology was analysed using the MASCOT program and the NCBI BLAST online search service. The database NCBInr 20060731 was used.

Western blotting

SW480 cells were treated with or without CAPE (10 μ g/mL) for 48 h. The cells were lysed in SDS-sample loading buffer and boiled at 100 °C for 5 min. The cell lysates were then subjected to SDS-PAGE. Proteins in the gel were then transferred onto PVDF membranes. The PVDF membranes were incubated for 2 h in blocking buffer (5% milk in 10 mmol/L Tris-HCl (pH = 7.5), 2.5 mmol/L EDTA (pH = 8.0), 50 mmol/L NaCl). The membranes were then incubated in antibodies against PSMA1, PSAT1, GNPDA1 or GPX1 (Sigma-Aldrich, United States) at a dilution of 1:1000 for 2 h at room temperature. After washing three times with washing buffer (TBS buffer containing 0.01% Tween 20), the membranes were incubated with HRP-conjugated antihuman IgG antibodies (Zhongshan Inc., Beijing, China) at a dilution of 1:5000 for 1 h at room temperature. Immunodetection was determined using the ECL-plus kit (Roche, United States) and autoradiography.

Immunofluorescence assay

SW480 cells grown on glass coverslips were treated with or without CAPE (10 μ g/mL) for 48 h under standard culture conditions as described above. The cells were washed with PBS and fixed with methanol for 20 min. Incubation with anti-PSMA1, and anti-PSAT1 monoclonal antibody (1:500) was carried out overnight at 4 °C. This step was followed by incubation with FITC-conjugated secondary antibody (1:1000) for 1 h at room temperature. DAPI was used to stain the nucleus. Images were captured using a laser scanning confocal microscope (Leica, Germany).

RESULTS

CAPE inhibits tumour cell growth and induces apoptosis To set up the cell culture system with CAPE treatment, SW480 cells were treated with CAPE at 5 μ g/mL or 10 μ g/mL, and cell growth was monitored daily by cell counting for a few days. Similar to a previous study^[2], 10 μ g/mL of CAPE effectively inhibited cell growth when compared to untreated control cells (data not shown). To determine if cell growth inhibition was caused by cell apoptosis, TUNEL assay was performed. We found a dose-dependent increase in cell apoptosis following treatment with CAPE (Figure 1A-D). Our data suggest that the growth inhibitory effect of CAPE may be associated with an increase in cell apoptosis.

Identification of differentially expressed proteins by the proteomics approach

To investigate the molecular mechanisms of the anticancer activity of CAPE, CAPE-treated colorectal cancer SW480 cells were analysed by a 2D-gel based proteomics approach. We used a cell viability assay to determine the optimum CAPE concentration of 10 μ g/mL for cell treatment over 48 h.

Protein expression profiles in SW480 cells with or without CAPE treatment were compared by 2D electrophoresis (2-DE). Approximately 250 protein spots in untreated (Figure 2A) and treated cells (Figure 2B) were detected on the Coomassie stained gels. All spots were matched by gel-to-gel comparison using PDQuest software, and the difference in the relative abundance of each protein spot was analysed. Four up-regulated and seven down-regulated protein spots in the treated SW480 cells were found repeatedly (Figure 2C). Those eleven highly repeatable proteins were excised and then identified by MALDI-TOF mass spectrometry and a database search. The seven down-regulated proteins in response to CAPE treatment were Triosephosphate isomerase, PSMA4 protein, guanine nucleotide-binding protein, PSAT1, PSMA1, myosin WVIIIB, and human tryptophanal-tRNA synthetase (Table 1). The up-regulated proteins were Annexin A4, glyceraldehyde-3-phosphate dehydrogenase,

WJG | www.wjgnet.com





Figure 1 Caffeic acid phenethyl ester induces colorectal cancer cell apoptosis. SW480 cells were treated with caffeic acid phenethyl ester (CAPE) in 24-well plates. For TUNEL staining, cells were treated without (A), with 2.5 μ g/mL (B), or 10 μ g/mL (C) CAPE for 48 h and cell apoptosis was examined using the TUNEL detection kit. Cell apoptosis was determined by counting TUNEL positive cells under a light microscope at × 40 objective (D). Results are representative of 3 independent experiments with similar results. ^aP < 0.05 vs controls; ^bP < 0.01, CAPE (2.5 μ g/mL) vs CAPE (10 μ g/mL).



Figure 2 Protein profiles of SW480 cells treated with caffeic acid phenethyl ester by two-dimensional PAGE. SW480 cells were treated without (A) or with (B) 10 μ g/mL caffeic acid phenethyl ester (CAPE) for 48 h and then harvested for 2D-PAGE analysis. 500 mg of cellular protein was applied to the IEF gel. After electrophoresis, the gels were stained with Coomassie brilliant blue R-250 and the proteins were analysed by PDQuest 2-D analysis software. The marked spots shown on the gels were the down-regulated proteins (shown by numbers 1-7) and the up-regulated proteins (shown by numbers 3-11). The relative abundance of each differentially expressed protein in the 2 gels was analysed by PDQuest (C). The first bar shown in the graph is the relative abundance of the proteins in CAPE-treated cells. Results are representative of 3 independent experiments with similar results.

Glucosamine-6-phosphate deaminase 1 (GNPDA1), and glutathione peroxidase (GPX-1) (Table 2).

Validation of differentially expressed proteins

To validate the above proteomic findings, the expression levels of some identified proteins were examined by Western blot analysis. Proteins were selected for further analysis based on both their high match score and their probable role in cell growth control. Similar to our earlier observation (Figure 2), the expression of PSMA1 and PSAT1 was down-regulated, and the expression of GNP-DA1 and GPX-1 was up-regulated in CAPE-treated cells (Figure 3A and B). The identity of the two tumorigenesis associated proteins, PSMA1 and PSAT1, were further confirmed by immunofluorescence assay. PSMA1 and PSAT1 were mainly expressed on the cell membrane and

He YJ et al. Differential proteins in CAPE-treated CRC cells

Table 1 Tuentineation of down-regulated proteins in 500 cens treated with carrier acid phenetify ester							
No.	Protein name	Accession No.	Matched peptides	Protein sequence coverage	Mascot score	MW/pl	
1	Triosephosphate	gi 15079533	FFVGGNWK	79%	131	26.8/6.51	
	Isomerase (Tim)		KQSLGELIGTLNAAK				
			VPADTEVVCAPPTAYIDFAR				
			IAVAAQNCYK				
			VTNGAFTGEISPGMIK				
			DCGATWVVLGHSER				
			RHVFGESDELIGQK				
			HVFGESDELIGQK				
			VAHALAEGLGVIACIGEK				
			VVLAYEPVWAIGTGK				
			TATPQQAQEVHEK				
			SNVSDAVAQSTR				
			IIYGGSVTGATCK				
			ELASQPDVDGFLVGGASLKPEFVDIINAK				
2	PSMA4 protein	gi 34783332	TTIFSPEGR	50%	70	29.6/7.56	
			LLDEVFFSEK				
			LNEDMACSVAGITSDANVLTNELR				
			YLLQYQEPIPCEQLVTALCDIK				
			RPFGVSLLYIGWDK				
			HYGFQLYQSDPSGNYGGWK				
			ATCIGNNSAAAVSMLK				
			QKEVEQLIK				
			KHEEEEAK				
3	Guanine nucleotide binding protein (G protein), beta	gi 5174447	GHNGWVTQIATTPQFPDMILSASR	80%	154	35.5/7.6	
			DETNYGIPQR				
			GHSHFVSDVVISSDGQFALSGSWDGTLR				
	polypeptide 2-like 1		LWDLTTGTTTR				
			DVLSVAFSSDNR				
			YTVQDESHSEWVSCVR				
			FSPNSSNPIIVSCGWDK				
			FSPNSSNPIIVSCGWDKLVK				
			VWNLANCK				
			TNHIGHTGYLNTVTVSPDGSLCASGGK				
			DGQAMLWDLNEGK				
			HLYTLDGGDIINALCFSPNR				
			YWLCAATGPSIK				
			IIVDELKQEVISISSK				
			AEPPQCISLAWSADGQILFAGYIDNLVK				
	D1 1 '	117000000	VWQVIIGIK OWWWECDCDAK	200/	70	40.0/7.5/	
4	Phosphoserine aminotransferase 1	g1 17390289	QV VNFGPGPAK	38%	79	40.9/7.56	
			LPHSVLLEIQK				
	(PSAII)						
			CADIVIGAVISAN				
			FGIINIVIIK				
			GAVLVCDWIJSINFLISKFVDVSK				
			COTIVEIIDNECCEVICEDOND				
F	Ductoscomo (nuccomo	ai 184009E0	NOVDNDVTVWSPOCR	50%	91	29.8/6.15	
5	macropain) subunit, alpha type, 1 (PSMA1)	gi 10490009	IHOIEVAMEAVK	50%	01		
			ILITY DIM INGISIAGE I ADAK				
			EVEDRDI DVCR				
			HMSEEMECNI NELVK				
			DI FETIYDDDDVSPEI FCI FERPOR				
			ΑΟΡΑΟΡΑΣΕΡΔΕΚΔΣΕΡΜΕΗ				





Conishideng® WJG | www.wjgnet.com

He YJ et al. Differential proteins in CAPE-treated CRC cells

6	Myosin XVIIIB	gi 51317366	DRQGTRPQAQGPGEGVRPGK EGAEPTNTVEKGNVSK STTGKAGESWDK MGQPQGKSGNAGEAR AGDGAGALETELEGPSQPALEK AGDGAGALETELEGPSQPALEKDAERPR RDQSIVALGWSGAGK QKAAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR QKAAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR QKAAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR QKAAAAFAQLQGAMEMLGISESEQR QKAAAAFAQLQGAMEMLGISESEQR QKAAAAFAQLQGAMEMLGISESEQR AAAAFAQLQGAMEMLGISESEQR QIQQMTFGPSR+ Oxidation (M) SFSSHHLSMASIMVVDSPGFQNPR + 2 Oxidation (M)/ NPTGGADEWQMR + 2 Oxidation (M) NPTGGADEWQMR + 2 Oxidation (M) NPTGGADEWQMR + 2 Oxidation (M) RTHALLSDVQLLLGTMEDGK HKLQEQLQVAQMR+ Oxidation (M) DSLIKMGEELSQAATSESQQR+ Oxidation (M) INEEAGDTERTQSALALSR + Oxidation (M) DMLLSPTLRPR+ Oxidation (M)	14%	75	28.7/6.45
7	Chain B, A Short Peptide Insertion Crucial For Angiostatic Activity Of Human Tryptophanyl-tRNA Synthetase	gi 42543731	DMLLSP1LKPKK EDFVDPWTVQTSSAKGIDYDK ATGQRPHHFLR GIFFSHR GIFFSHRDMNQVLDAYENK KPFYLYTGR GPSSEAMHVGHLIPFIFTK WLQDVFNVPLVIQMTDDEK+ Oxidation (M) TFIFSDLDYMGMSSGFYK + Oxidation (M) HVTFNQVK GIFGFTDSDCIGK ISFPAIQAAPSFSNSFPQIFR IGYPKPALLHSTFFPALQGAQTK MSASDPNSSIFLTDTAK ALIEVLQPLIAEHQAR KLSFDFQ	56%	79	44.9/6.41

in the cytosol (Figure 3B and C). After CAPE treatment, the expression levels of PSMA1 and PSAT1 were altered, although the cellular localisation of these proteins did not change (Figure 3B and C).

DISCUSSION

Propolis has been used in folk medicine since ancient times and has been noted to exhibit immunoregulatory, anti-bacterial, anti-inflammatory, and anti-tumorigenic activities in different models^[15-17]. CAPE is a component of propolis and is therefore implicated in the activity of propolis. CAPE has been shown to selectively target tumour cells and to inhibit tumour cell proliferation. In addition, CAPE has been demonstrated to induce apoptosis in different types of tumours including breast cancer^[18], myeloid leukaemia^[13], cervical cancer^[12], hepatocarcinoma cell^[19], cholangiocarcinoma^[7], and glioma^[20].

In our previous studies, we demonstrated that CAPE could inhibit colorectal cancer cell proliferation by inducing cell cycle arrest and apoptosis^[2]. Recently, it was shown that CAPE was a specific inhibitor of nuclear factor κ B, inducing apoptosis *via* activation of the Fas signalling pathway in human tumour cells^[21]. Other signalling pathways may also be involved^[2,11,13,19]. To investigate the molecular mechanisms of the anti-cancer activity of CAPE, we compared the protein expression profiles of treated SW480 cells using 2D electrophoresis. Highly repeatable protein spots were selected and identified by MALDI-TOF mass spectrometry and online database searching.

PSAT1 belongs to subgroup IV of the aminotransferases and plays a crucial role in linking the central catabolic pathways (glycolysis) and amino acid biosynthesis pathways. PSAT1 catalyses the second step in the biosynthesis of the amino acid, serine, which in turn, is the crucial carbon source for purine nucleotides, phosphatidylcholine, phosphatidylserine, and other cellular metabolites. PSAT1 is weakly expressed in the normal colon, but overexpressed in colon cancer with increased expression as disease progresses^[22,23]. PSAT1 expression was shown to be up-regulated during the colorectal adenoma-to-carcinoma sequence by proteomic technology^[24]. Recently, it has been reported that the overexpression of PSAT1 stimulates cell growth and increases the chemoresistance of colon cancer cells^[25], indicating that overexpression of

Table 2	Identification of up-regu	lated proteins	in SW480 cells treated with caffeic acid p	henethyl ester		
No.	Protein name	Accession No.	Matched peptides	Protein sequence coverage	Mascot score	MW/pl
8	Annexin A4	gi 12652859	AASGFNAMEDAQTLR GLGTDEDAIISVLAYR GAGTDEGCLIEILASR ISQTYQQQYGR SLEDDIRSDTSFMFQR + Oxidation (M) SDTSFMFQR+ Oxidation (M) VLVSLSAGGR DEGNYLDDALVR QDAQDLYEAGEK FLTVLCSR NRNHLLHVFDEYK NHLLHVFDEYK NHLLHVFDEYK SETSGSFEDALLAIVK NKSAYFAEK GLGTDDNTLIR	56%	105	36.2/5.65
9	Glyceraldehyde- 3-phosphate dehydrogenase	gi 31645	VMVSRAEIDMLDIR+2 Oxidation (M) AEIDMLDIR LVINGNPITIFQERDPSK WGDAGAEYVVESTGVFTTMEK RVIISAPSADAPMFVMGVNHEK IISNASCTTNCLAPLAK VIHDNFGIVEGLMTTVHAITATQK GALQNIIPASTGAAK VPTANVSVVDLTCR LISWYDNEFGYSNR VVDI MAHMASK+2 Oxidation (M)	46%	76	36.2/8.28
10	Glucosamine-6- phosphate deaminase 1 (GNPDA1)	gi 18490843	IIQFNPGPEK YFTLGLPTGSTPLGCYK TFNMDEYVGLPR AAGGIELFVGGIGPDGHIAFNEPGSSLVSR TLAMDTILANAR VPTMALTVGVGTVMDAR EVMILITGAHKAFALYK AIEEGVNHMWTVSAFQQHPR TVFVCDEDATLELK ETEKSQSSK	54%	90	32.8/6.42
11	Glutathione peroxidase 1 (GPX1)	gi 14717805	GLVVLGFPCNQFGHQENAK YVRPGGGFEPNFMLFEK CEVNGAGAHPLFAFLR EALPAPSDDATALMTDPKLITWSPVCR LITWSPVCR FLVGPDGVPLR FLVGPDGVPLRR RFQTIDIEPDIEALLSQGPSCA	56%	70	22.2/6.15

He YJ et al. Differential proteins in CAPE-treated CRC cells

PSAT1 may be involved in tumorigenesis and promotes cell growth. In contrast, down-regulation of PAST1 in CAPE-treated colorectal cancer cells may be associated with cell growth inhibition.

Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in non-lysosomal pathways. PSMA1 is a subunit that is strategically located at the mouth of the core of the proteasome barrel. While PSMA1 is not part of the catalytic machinery of the proteasome, it likely plays a role in gating the entry of proteins into the barrel. PSMA1 has been shown to bind specifically with Notch 3 protein in a yeast two-hybrid assay, which results in the inhibition of proteasome activity^[26]. PSMA1 has been reported to be over-expressed in breast cancer tissue compared to adjacent

normal tissue^[27], suggesting that PSMA1 may be involved in tumorigenesis. Similar to PSAT1, PSMA1 was downregulated in CAPE-treated CRC cells, suggesting that PSMA1 is not only an important regulator of biological processes, but also involved in the anti-cancer activity of CAPE.

GNPDA or glucosamine-6-phosphate isomerase (GNPI) is an allosteric enzyme that catalyses the reversible conversion of D-glucosamine-6-phosphate into D-fructose-6-phosphate and ammonium^[28]. Although GNPI has been found to be expressed in human tissues and some cancer cell lines ubiquitously^[29], its role in tumorigenesis and the anti-cancer effect of CAPE is unknown. However, lower expression of another upregulated protein, GPX1, a selenium-containing antioxidant enzyme, is associated with aggressiveness and poor





Figure 3 Validation of differentially expressed proteins in SW480 treated with caffeic acid phenethyl ester. SW480 cells were treated without (control) and with 10 μ g/mL CAPE for 48 h and then harvested for Western blotting (A and B) or immunofluorescence assay (C and D). For Western blotting, beta-actin was included as the internal control. Densitometric analysis was performed and the integrated density values are presented as the ratio of each protein over the beta-actin protein (B). For the immunofluorescence assay, SW480 cells were grown on glass coverslips and treated without (control) or with CAPE (10 μ g/mL) for 48 h. The cells were washed with PBS and fixed with methanol. Anti-PSMA1 (A), and anti-PSAT1 (B) monoclonal antibodies were applied as the primary antibodies, and then, FITC-conjugated secondary antibodies were used. DAPI was used to stain the nucleus. Results are representative of 2 independent experiments with similar results. PSMA1: Proteasome subunit alpha 1; PSAT1: Phosphoserine aminotransferase 1.

survival in patients with cancer^[30-32]. GPX-1 may have cancer-supressing effects and up-regulation of GPX1 in CAPE-treated colorectal cancer cells might also be associated with the anti-cancer effect of CAPE.

In conclusion, we found that CAPE induced cell apoptosis and a differential protein expression profile. In particular, CAPE treatment resulted in down-regulation of proteins previously implicated in tumorigenesis. Down-regulated PSAT1 and PSMA1 and up-regulated GPX-1 in CAPE treated-colorectal cancer cells may be potential molecular targets of CAPE and involved in the anti-cancer effect of CAPE.

ACKNOWLEDGMENTS

We thank Lei Zhang for excellent technical assistance and Emeka Okeke at the University of Manitoba in Canada for English language editing.

COMMENTS

Background

Colorectal cancer is one of the most commonly diagnosed malignancies and the third deadliest cancer in humans. Caffeic acid phenethyl ester (CAPE) is a phenolic antioxidant, which is known to suppress the growth of tumor cells and induce cell apoptosis. However, the molecular mechanisms of the anti-cancer activity of CAPE are unclear.

Research frontiers

CAPE is an active component of propolis and has various biological and pharmacological functions including immunoregulatory, anti-inflammatory, anti-viral, anti-bacterial, and anti-cancer activities. Several studies have demonstrated that CAPE has anti-proliferative effects by inducing apoptosis in various tumour cells *in vitro* and *in vivo*. CAPE also inhibits the development of azoxymethaneinduced aberrant crypts in the colon of rats.

Innovations and breakthroughs

Based on a proteomic approach, several altered proteins were identified in CAPE-treated human colorectal cancer cells. Phosphoserine aminotransferase 1 (PSAT1) and Proteasome subunit alpha 1 (PSMA1), have been shown to be overexpressed in human cancer tissues, while low expression of Glutathione peroxidase (GPX-1) is known to be associated with aggressiveness and poor survival in patients with cancer. Down-regulated PSAT1 and PSMA1 and up-regulated GPX-1 in CAPE treated-colorectal cancer cells may be potential molecular targets of CAPE and involved in the anti-cancer effect of CAPE.

Applications

These findings suggest that CAPE mediates its anti-cancer effect by regulating the expression of important molecules.

Terminology

Proteomics is the study of the structure and function of proteins in a cell or tissue at a specific time under certain pre-defined conditions. CAPE is a natural phenolic chemical compound. It is found in a variety of plants and is also a component of propolis found in honeybee hives.

Peer review

The authors of this paper studied the mechanism involved in the inhibition by CAPE of colorectal cancer cells, and identified differential protein expression with or without CAPE-treatment. They concluded that CAPE-treatment down-regulated 7 proteins including PSAT1 and PSMA1 that played important roles in tumorigenesis but up-regulated 4 proteins including GNPDA1 and GPX1. The article is well written. Experimental design was logically followed through. Method and results were well presented.

REFERENCES

- Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]
- 2 He YJ, Liu BH, Xiang DB, Qiao ZY, Fu T, He YH. Inhibitory effect of caffeic acid phenethyl ester on the growth of SW480 colorectal tumor cells involves beta-catenin associated signaling pathway down-regulation. *World J Gastroenterol* 2006; 12: 4981-4985 [PMID: 16937493]
- 3 Lee YJ, Liao PH, Chen WK, Yang CY. Preferential cytotoxicity of caffeic acid phenethyl ester analogues on oral cancer cells. *Cancer Lett* 2000; **153**: 51-56 [PMID: 10779629 DOI: 10.1016/S0304-3835(00)00389-X]
- 4 **Chen YJ**, Shiao MS, Wang SY. The antioxidant caffeic acid phenethyl ester induces apoptosis associated with selective scavenging of hydrogen peroxide in human leukemic HL-60 cells. *Anticancer Drugs* 2001; **12**: 143-149 [PMID: 11261888 DOI: 10.1097/00001813-200102000-00008]
- 5 Nagaoka T, Banskota AH, Tezuka Y, Saiki I, Kadota S. Selective antiproliferative activity of caffeic acid phenethyl ester analogues on highly liver-metastatic murine colon 26-L5 carcinoma cell line. *Bioorg Med Chem* 2002; **10**: 3351-3359 [PMID: 12150882 DOI: 10.1016/S0968-0896(02)00138-4]
- 6 Usia T, Banskota AH, Tezuka Y, Midorikawa K, Matsushige K, Kadota S. Constituents of Chinese propolis and their antiproliferative activities. J Nat Prod 2002; 65: 673-676 [PMID: 12027739 DOI: 10.1021/np010486c]
- 7 Onori P, DeMorrow S, Gaudio E, Franchitto A, Mancinelli R, Venter J, Kopriva S, Ueno Y, Alvaro D, Savage J, Alpini G, Francis H. Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. *Int J Cancer* 2009; **125**: 565-576 [PMID: 19358267 DOI: 10.1002/ijc.24271]

- 8 Orsolić N, Terzić S, Mihaljević Z, Sver L, Basić I. Effects of local administration of propolis and its polyphenolic compounds on tumor formation and growth. *Biol Pharm Bull* 2005; 28: 1928-1933 [PMID: 16204948 DOI: 10.1248/bpb.28.1928]
- 9 Kuo HC, Kuo WH, Lee YJ, Lin WL, Chou FP, Tseng TH. Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. *Cancer Lett* 2006; 234: 199-208 [PMID: 15885897 DOI: 10.1016/j.canlet.2005.03.046]
- 10 Borrelli F, Izzo AA, Di Carlo G, Maffia P, Russo A, Maiello FM, Capasso F, Mascolo N. Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon. *Fitoterapia* 2002; 73 Suppl 1: S38-S43 [PMID: 12495708 DOI: 10.1016/S0367-326X(02)00189-2]
- 11 Lee Y, Shin DH, Kim JH, Hong S, Choi D, Kim YJ, Kwak MK, Jung Y. Caffeic acid phenethyl ester-mediated Nrf2 activation and IkappaB kinase inhibition are involved in NFkappaB inhibitory effect: structural analysis for NFkappaB inhibition. *Eur J Pharmacol* 2010; **643**: 21-28 [PMID: 20599928 DOI: 10.1016/j.ejphar.2010.06.016]
- 12 Hung MW, Shiao MS, Tsai LC, Chang GG, Chang TC. Apoptotic effect of caffeic acid phenethyl ester and its ester and amide analogues in human cervical cancer ME180 cells. *Anticancer Res* 2003; 23: 4773-4780 [PMID: 14981925]
- 13 Jin UH, Song KH, Motomura M, Suzuki I, Gu YH, Kang YJ, Moon TC, Kim CH. Caffeic acid phenethyl ester induces mitochondria-mediated apoptosis in human myeloid leukemia U937 cells. *Mol Cell Biochem* 2008; **310**: 43-48 [PMID: 18060475 DOI: 10.1007/s11010-007-9663-7]
- 14 Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after oneor two-dimensional gel electrophoresis. *Anal Biochem* 1992; 203: 173-179 [PMID: 1524213]
- 15 Orsolić N, Knezević AH, Sver L, Terzić S, Basić I. Immunomodulatory and antimetastatic action of propolis and related polyphenolic compounds. *J Ethnopharmacol* 2004; 94: 307-315 [PMID: 15325736 DOI: 10.1016/j.jep.2004.06.006]
- 16 Orsolić N, Saranović AB, Basić I. Direct and indirect mechanism(s) of antitumour activity of propolis and its polyphenolic compounds. *Planta Med* 2006; 72: 20-27 [PMID: 16450291 DOI: 10.1055/s-2005-873167]
- Sforcin JM, Bankova V. Propolis: is there a potential for the development of new drugs? J Ethnopharmacol 2011; 133: 253-260 [PMID: 20970490 DOI: 10.1016/j.jep.2010.10.032]
- 18 Wu J, Omene C, Karkoszka J, Bosland M, Eckard J, Klein CB, Frenkel K. Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer. *Cancer Lett* 2011; 308: 43-53 [PMID: 21570765 DOI: 10.1016/j.canlet.2011.04.012]
- 19 Chung TW, Moon SK, Chang YC, Ko JH, Lee YC, Cho G, Kim SH, Kim JG, Kim CH. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. *FASEB J* 2004; 18: 1670-1681 [PMID: 15522912 DOI: 10.1096/fj.04-2126com]
- 20 Lee YJ, Kuo HC, Chu CY, Wang CJ, Lin WC, Tseng TH. Involvement of tumor suppressor protein p53 and p38 MAPK in caffeic acid phenethyl ester-induced apoptosis of C6 glioma cells. *Biochem Pharmacol* 2003; 66: 2281-2289 [PMID: 14637186]
- 21 Watabe M, Hishikawa K, Takayanagi A, Shimizu N, Nakaki T. Caffeic acid phenethyl ester induces apoptosis by inhibition of NFkappaB and activation of Fas in human breast cancer MCF-7 cells. *J Biol Chem* 2004; **279**: 6017-6026 [PMID: 14625298 DOI: 10.1074/jbc.M306040200]
- 22 Ojala P, Sundström J, Grönroos JM, Virtanen E, Talvinen K, Nevalainen TJ. mRNA differential display of gene expression in colonic carcinoma. *Electrophoresis* 2002; 23: 1667-1676 [PMID: 12179986]

- 23 Friederichs J, Rosenberg R, Mages J, Janssen KP, Maeckl C, Nekarda H, Holzmann B, Siewert JR. Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression. *Int J Colorectal Dis* 2005; 20: 391-402 [PMID: 15883783 DOI: 10.1007/s00384-004-0722-1]
- 24 Roth U, Razawi H, Hommer J, Engelmann K, Schwientek T, Müller S, Baldus SE, Patsos G, Corfield AP, Paraskeva C, Hanisch FG. Differential expression proteomics of human colorectal cancer based on a syngeneic cellular model for the progression of adenoma to carcinoma. *Proteomics* 2010; 10: 194-202 [PMID: 19899082 DOI: 10.1002/pmic.200900614]
- 25 Vié N, Copois V, Bascoul-Mollevi C, Denis V, Bec N, Robert B, Fraslon C, Conseiller E, Molina F, Larroque C, Martineau P, Del Rio M, Gongora C. Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. *Mol Cancer* 2008; 7: 14 [PMID: 18221502 DOI: 10.1186/1476-4598-7-14]
- 26 Zhang Y, Jia L, Lee SJ, Wang MM. Conserved signal peptide of Notch3 inhibits interaction with proteasome. *Biochem Biophys Res Commun* 2007; 355: 245-251 [PMID: 17292860 DOI: 10.1016/j.bbrc.2007.01.151]
- 27 Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T, Dong L, Tang E, Yang H. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome sub-

units (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. *Breast Cancer Res Treat* 2007; **104**: 21-30 [PMID: 17004105 DOI: 10.1007/s10549-006-9393-7]

- 28 Arreola R, Valderrama B, Morante ML, Horjales E. Two mammalian glucosamine-6-phosphate deaminases: a structural and genetic study. *FEBS Lett* 2003; 551: 63-70 [PMID: 12965206]
- 29 Zhang J, Zhang W, Zou D, Chen G, Wan T, Li N, Cao X. Cloning and functional characterization of GNPI2, a novel human homolog of glucosamine-6-phosphate isomerase/oscillin. J Cell Biochem 2003; 88: 932-940 [PMID: 12616532 DOI: 10.1002/jcb.10444]
- 30 Min SY, Kim HS, Jung EJ, Jung EJ, Jee CD, Kim WH. Prognostic significance of glutathione peroxidase 1 (GPX1) down-regulation and correlation with aberrant promoter methylation in human gastric cancer. *Anticancer Res* 2012; 32: 3169-3175 [PMID: 22843889]
- 31 Lei XG, Cheng WH, McClung JP. Metabolic regulation and function of glutathione peroxidase-1. *Annu Rev Nutr* 2007; 27: 41-61 [PMID: 17465855 DOI: 10.1146/annurev. nutr.27.061406.093716]
- 32 Hu Y, Benya RV, Carroll RE, Diamond AM. Allelic loss of the gene for the GPX1 selenium-containing protein is a common event in cancer. *J Nutr* 2005; **135**: 3021S-3024S [PMID: 16317164]

P- Reviewer: Pichler M S- Editor: Qi Y L- Editor: Webster JR E- Editor: Wang CH







Published by Baishideng Publishing Group Inc

8226 Regency Drive, Pleasanton, CA 94588, USA Telephone: +1-925-223-8242 Fax: +1-925-223-8243 E-mail: bpgoffice@wjgnet.com Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx http://www.wjgnet.com



ISSN 1007-9327

9 771007

